DarioHealth Corp.

Equities

DRIO

US23725P2092

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
1.73 ^USD	-1.14%		+6.13%	+0.58%

Apr. 25	DarioHealth Corp. Publishes New Peer-Reviewed Study That Deepens the Body of Evidence That Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes	CI
Apr. 18	DarioHealth Corp. Signs Two Employers for Cardiometabolic Suite with Integrated Glp-1 Solution	CI

DarioHealth Corp. Appoints Dennis A. Matheis to Its Board of Directors

July 06, 2020 at 08:30 am EDT

DarioHealth Corp. announced that the company has appointed Dennis A. Matheis to its Board of Directors, effective July 2, 2020. Mr. Matheis brings to the Dario Board nearly 30 years of experience leading regional and national health care plans and related organizations. He currently serves as President of Optima Health, a division of Sentara Healthcare which has more than 850,000 members and a network of over 26,000 providers. He also serves as Executive Vice President of Sentara Healthcare.

Latest news about DarioHealth Corp.

DarioHealth Corp. Publishes New Peer-Reviewed Study That Deepens the Body of Evidence That Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes	Apr. 25	CI
DarioHealth Corp. Signs Two Employers for Cardiometabolic Suite with Integrated Glp-1 Solution	Apr. 18	CI
DarioHealth Corp. Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health	Apr. 10	CI
Two National Employers Select DarioHealth Corp.'S Integrated Chronic Condition Solution to Improve Employee Health	Apr. 02	CI
Transcript : DarioHealth Corp., 2023 Earnings Call, Mar 28, 2024	Mar. 28
DarioHealth Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
North American Morning Briefing : Investors -2-	Mar. 21	DJ
DarioHealth Corp. Announces Two New Clinical Studies Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes 2024	Mar. 12	CI
Transcript : DarioHealth Corp., Twill, Inc. - M&A Call	Feb. 21
DarioHealth Corp. Appoints Tomer Ben-Kiki as Chief Operating Officer	Feb. 21	CI
DarioHealth Corp. announced that it has received $22.422 million in funding	Feb. 20	CI
DarioHealth Corp. acquired Twill, Inc. for $34.4 million.	Feb. 20	CI
DarioHealth Corp. announced that it expects to receive $22.422 million in funding	Feb. 14	CI
DarioHealth to Provide Diabetes, Weight-Control Services for Food Services Union Members	Jan. 11	MT
Regional Union Selects DarioHealth Corp.'s Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support	Jan. 11	CI
National Employer Selects Dariohealth Corp. Cardiometabolic and GLP-1 Solutions to Improve Employee Health	Dec. 05	CI
DarioHealth Corp. Contracts with New Employer for Cardiometabolic Solution	Nov. 27	CI
Transcript : DarioHealth Corp., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (DRIO) DARIOHEALTH Posts Q3 Revenue $3.5M, vs. Street Est of $5.4M	Nov. 02	MT
DarioHealth Corp. Provides Revenue Guidance for the Year 2024	Nov. 02	CI
DarioHealth Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
DarioHealth Launches New Blood Sugar Meter for Apple iPhone 15 Users	Nov. 01	MT
Transcript : DarioHealth Corp. - Analyst/Investor Day	23-10-17
DarioHealth Says Digital Health Solution Cut Hospital Readmissions by 36% for Users With Type 2 Diabetes	23-10-17	MT

Chart DarioHealth Corp.

Duration

Period

More charts

Company Profile

DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-15 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for DarioHealth Corp.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.75 USD

Average target price

5.667 USD

Spread / Average Target

+223.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
DARIOHEALTH CORP.	+0.58%	51.92M
ABBOTT LABORATORIES	-5.51%	182B
MEDTRONIC PLC	+2.33%	111B
BECTON, DICKINSON AND COMPANY	-3.62%	68.48B
DEXCOM, INC.	+1.52%	49.69B
CENCORA, INC.	+8.06%	44.46B
HOYA CORPORATION	+2.33%	40.67B
METTLER-TOLEDO INTERNATIONAL, INC.	+23.35%	31.22B
WEST PHARMACEUTICAL SERVICES, INC.	+0.67%	26.09B
TERUMO CORPORATION	+15.30%	25.32B

Other Medical Equipment, Supplies & Distribution